Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 virus-like particles

Clinical and Vaccine Immunology

Volumn 14, Issue 8, 2007, Pages 984-989

  García Piñeres, Alfonso ^a   Hildesheim, Allan ^b   Dodd, Lori ^b   Kemp, Troy J ^a   Williams, Marcus ^a   Harro, Clayton ^c   Lowy, Douglas R ^d   Schiller, John T ^d   Pinto, Ligia A ^a,e  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NOVAVAX; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WART VIRUS VACCINE; CAPSID PROTEIN; CHEMOKINE; CYTOKINE; L1 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PAPILLOMA VIRUS VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; ADOLESCENT; BLOOD; CLUSTER ANALYSIS; IMMUNOLOGY; SERODIAGNOSIS; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; VIRION; VIROLOGY;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CAPSID PROTEINS; CHEMOKINES; CLUSTER ANALYSIS; CYTOKINES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TH1 CELLS; TH2 CELLS; TREATMENT OUTCOME; VACCINATION; VIRION;

EID: 35248841096     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00090-07     Document Type: Article

References (29)

1. Brown, D. R., K. H. Fife, C. M. Wheeler, L. A. Koutsky, L. M. Lupinacci, R. Railkar, G. Suhr, E. Barr, A. Dicello, W. Li, J. F. Smith, A. Tadesse, and K. U. Jansen. 2004. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22:2936-2942.
2. Da Silva, D. M., M. P. Velders, J. D. Nieland, J. T. Schiller, B. J. Nickoloff, and W. M. Kast. 2001. Physical interaction of human papillomavirus virus-like particles with immune cells. Int. Immunol. 13:633-641.
3. De Rosa, S. C., F. X. Lu, J. Yu, S. P. Perfetto, J. Falloon, S. Moser, T. G. Evans, R. Koup, C. J. Miller, and M. Roederer. 2004. Vaccination in humans generates broad T cell cytokine responses. J. Immunol. 173:5372-5380.
4. Emeny, R. T., C. M. Wheeler, K. U. Jansen, W. C. Hunt, T. M. Fu, J. F. Smith, S. MacMullen, M. T. Esser, and X. Paliard. 2002. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J. Virol. 76:7832-7842.
5. Evans, T. G., W. Bonnez, R. C. Rose, S. Koenig, L. Demeter, J. A. Suzich, D. O'Brien, M. Campbell, W. I. White, J. Balsley, and R. C. Reichman. 2001. A phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183:1485-1493.
6. Fausch, S. C., D. M. Da Silva, and W. M. Kast. 2003. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res. 63:3478-3482.
7. Fife, K. H., C. M. Wheeler, L. A. Koutsky, E. Barr, D. R. Brown, M. A. Schiff, N. B. Kiviat, K. U. Jansen, H. Barber, J. F. Smith, A. Tadesse, K. Giacoletti, P. R. Smith, G. Suhr, and D. A. Johnson. 2004. Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 22:2943-2952.
8. Garcia-Pineres, A. J., A. Hildesheim, M. Trivett, M. Williams, L. Wu, V. N. Kewalramani, and L. A. Pinto. 2006. Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine. Eur. J. Immunol. 36:437-445.
9. Harper, D. M., E. L. Franco, C. M. Wheeler, A. B. Moscicki, B. Romanowski, C. M. Roteli-Martins, D. Jenkins, A. Schuind, S. A. Costa Clemens, and G. Dubin. 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255.
10. Harro, C. D., Y. Y. Pang, R. B. Roden, A. Hildesheim, Z. Wang, M. J. Reynolds, T. C. Mast, R. Robinson, B. R. Murphy, R. A. Karron, J. Dillner, J. T. Schiller, and D. R. Lowy. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:284-292.
11. Julkunen, I., T. Sareneva, J. Pirhonen, T. Ronni, K. Melen, and S. Matikainen. 2001. Molecular pathogenesis of influenza A virus infection and virus-induced regulation of cytokine gene expression. Cytokine Growth Factor Rev. 12:171-180.
12. Kaufmann, A., R. Salentin, R. G. Meyer, D. Bussfeld, C. Pauligk, H. Fesq, P. Hofmann, M. Nain, D. Gemsa, and H. Sprenger. 2001. Defense against influenza A virus infection: essential role of the chemokine system. Immunobiology 204:603-613.
13. Kirnbauer, R., F. Booy, N. Cheng, D. R. Lowy, and J. T. Schiller. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA 89:12180-12184.
14. Kirnbauer, R., J. Taub, H. Greenstone, R. Roden, M. Durst, L. Gissmann, D. R. Lowy, and J. T. Schiller. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:6929-6936.
15. Koutsky, L. A., K. A. Ault, C. M. Wheeler, D. R. Brown, E. Barr, F. B. Alvarez, L. M. Chiacchierini, and K. U. Jansen. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347:1645-1651.
16. Lenz, P., P. M. Day, Y. Y. Pang, S. A. Frye, P. N. Jensen, D. R. Lowy, and J. T. Schiller. 2001. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166:5346-5355.
17. Lenz, P., C. D. Thompson, P. M. Day, S. M. Bacot, D. R. Lowy, and J. T. Schiller. 2003. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin. Immunol. 106:231-237.
18. Mao, C., L. A. Koutsky, K. A. Ault, C. M. Wheeler, D. R. Brown, D. J. Wiley, F. B. Alvarez, O. M. Bautista, K. U. Jansen, and E. Barr. 2006. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol. 107:18-27.
19. Pastrana, D. V., C. B. Buck, Y. Y. Pang, C. D. Thompson, P. E. Castle, P. C. FitzGerald, S. Kruger Kjaer, D. R. Lowy, and J. T. Schiller. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205-216.
20. Pinto, L. A., P. E. Castle, R. B. Roden, C. D. Harro, D. R. Lowy, J. T. Schiller, D. Wallace, M. Williams, W. Kopp, I. H. Frazer, J. A. Berzofsky, and A. Hildesheim. 2005. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 23:3555-3564.
21. Pinto, L. A., J. Edwards, P. E. Castle, C. D. Harro, D. R. Lowy, J. T. Schiller, D. Wallace, W. Kopp, J. W. Adelsberger, M. W. Baseler, J. A. Berzofsky, and A. Hildesheim. 2003. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. 188:327-338.
22. Poland, G. A., R. M. Jacobson, L. A. Koutsky, G. M. Tamms, R. Railkar, J. F. Smith, J. T. Bryan, P. F. Cavanaugh, Jr., K. U. Jansen, and E. Barr. 2005. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial. Mayo Clin. Proc. 80:601-610.
23. Powers, D. C., J. E. McElhaney, O. A. Florendo, Jr., M. C. Manning, C. M. Upshaw, D. W. Bentley, and B. E. Wilkinson. 1997. Humoral and cellular immune responses following vaccination with purified recombinant hemagglutinin from influenza A (H3N2) virus. J. Infect. Dis. 175:342-351.
24. Querec, T., S. Bennouna, S. Alkan, Y. Laouar, K. Gorden, R. Flavell, S. Akira, R. Ahmed, and B. Pulendran. 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 203:413-424.
25. Ronni, T., T. Sareneva, J. Pirhonen, and I. Julkunen. 1995. Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells. J. Immunol. 154:2764-2774.
26. Tomson, T. T., R. B. Roden, and T. C. Wu. 2004. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr. Opin. Investig. Drugs 5:1247-1261.
27. Yang, R., F. M. Murillo, M. J. Delannoy, R. L. Blosser, W. H. Yutzy, S. Uematsu, K. Takeda, S. Akira, R. P. Viscidi, and R. B. Roden. 2005. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J. Immunol. 174:7912-7919.
28. Yao, Q., R. Zhang, L. Guo, M. Li, and C. Chen. 2004. Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine. J. Immunol. 173:1951-1958.
29. Zinkernagel, R. M., M. F. Bachmann, T. M. Kundig, S. Oehen, H. Pirchet, and H. Hengartner. 1996. On immunological memory. Annu. Rev. Immunol. 14:333-367.